Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Beersel – page 53

1 950 clinical trials in Beersel, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Beersel at a glance
1 950
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 950 trials in Beersel

Open in trial search

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:KITE-363
  • Sponsor:Kite Pharma Inc.

Study on Lowering INR to Reduce Bleeding in Patients with Mechanical Aortic Valves Using Warfarin, Acenocoumarol, and Phenprocoumon

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Hamilton Health Sciences Corporation

Study of Bicalutamide and Abemaciclib for Patients with Advanced Androgen Receptor Positive Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:UZ Leuven

Study on Reducing Rituximab Dosage for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:UZ Leuven

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Leonabio Inc.

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Pneumonia

Recruiting

Study on Ceftriaxone Dosing for Patients with Severe Community-Acquired Pneumonia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ceftriaxone
  • Sponsor:UZ Leuven

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Study on Indocyanine Green for Evaluating Surgical Margins in Patients Undergoing Breast-Conserving Surgery for Early Invasive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Institut Jules Bordet

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Beersel

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, exploring innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Episode Reduction
  • Long-term Control

Research evaluating a novel treatment's effectiveness in reducing the frequency of herpes episodes over a 12-month period, with particular attention to patients experiencing six or more outbreaks annually.

02 Therapeutic Development

Conducting controlled studies to assess the efficacy of 2LHERP®, a potential breakthrough treatment for managing recurring viral infections.

  • Treatment Efficacy
  • Symptom Control
  • Patient Response

The research employs rigorous methodology including placebo control and double-blind protocols to ensure reliable evaluation of treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.